LifeStance Health Group (NASDAQ:LFST) Now Covered by Analysts at BMO Capital Markets

Equities research analysts at BMO Capital Markets began coverage on shares of LifeStance Health Group (NASDAQ:LFST) in a note issued to investors on Thursday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $8.00 price target on the stock. BMO Capital Markets’ price target suggests a potential upside of 21.67% from the stock’s current price.

LFST has been the topic of a number of other reports. Wall Street Zen lowered shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. UBS Group boosted their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of LifeStance Health Group in a research report on Wednesday, October 8th. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Finally, BTIG Research raised their price target on LifeStance Health Group from $8.00 to $9.00 and gave the company a “buy” rating in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

LifeStance Health Group Price Performance

NASDAQ LFST traded up $0.14 on Thursday, reaching $6.58. The company’s stock had a trading volume of 895,027 shares, compared to its average volume of 1,995,086. LifeStance Health Group has a 52 week low of $3.74 and a 52 week high of $8.30. The company has a current ratio of 1.58, a quick ratio of 1.48 and a debt-to-equity ratio of 0.18. The firm has a market cap of $2.56 billion, a PE ratio of -218.83 and a beta of 1.15. The business has a 50-day moving average price of $5.36 and a 200 day moving average price of $5.27.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Thursday, November 6th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. The company had revenue of $363.81 million for the quarter, compared to the consensus estimate of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The firm’s revenue for the quarter was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.02) EPS. LifeStance Health Group has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts expect that LifeStance Health Group will post -0.18 EPS for the current year.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, major shareholder Summit Partners L. P sold 8,407,643 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.07, for a total value of $42,626,750.01. Following the completion of the sale, the insider owned 33,524,715 shares in the company, valued at $169,970,305.05. This trade represents a 20.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Darren M. Black sold 8,407,643 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.07, for a total value of $42,626,750.01. Following the completion of the sale, the director owned 33,524,715 shares in the company, valued at $169,970,305.05. This represents a 20.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 20,407,643 shares of company stock valued at $103,466,750. 3.20% of the stock is owned by corporate insiders.

Institutional Trading of LifeStance Health Group

Several hedge funds and other institutional investors have recently bought and sold shares of the business. AustralianSuper Pty Ltd bought a new stake in shares of LifeStance Health Group during the 3rd quarter valued at $17,056,000. Vanguard Group Inc. raised its position in LifeStance Health Group by 19.5% during the third quarter. Vanguard Group Inc. now owns 14,613,535 shares of the company’s stock valued at $80,374,000 after purchasing an additional 2,383,728 shares in the last quarter. Dimensional Fund Advisors LP grew its position in LifeStance Health Group by 27.2% in the third quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after acquiring an additional 1,790,694 shares during the last quarter. Barclays PLC increased its position in LifeStance Health Group by 74.7% during the 3rd quarter. Barclays PLC now owns 3,508,552 shares of the company’s stock worth $19,297,000 after purchasing an additional 1,499,687 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of LifeStance Health Group by 280.1% in the 2nd quarter. Bank of America Corp DE now owns 1,767,051 shares of the company’s stock valued at $9,136,000 after acquiring an additional 1,302,140 shares during the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.